GlobeNewswire Inc | Mar 11, 2021 07:10AM EST

March 11, 2021

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit.

Event Q1 Investor SummitDate March 23-25th, 2021Presentation March 23rd @ 1:00PM ETLocation https://zoom.us/webinar/register/WN_xb629I-QTUia3uuDPvCo6A

About The Investor SummitThe Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

About Artelo BiosciencesArtelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the developmentand commercialization of proprietary therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available atwww.artelobio.comand Twitter: @ArteloBio.

Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Investor Summit Contact:Brittney Blocker at brittney@investorsummitgroup.com

Wire Service ContactInvestorWire (IW) Los Angeles, Californiawww.InvestorWire.com212.418.1217 OfficeEditor@InvestorWire.com